CarlosEduardoArce-LaraMD

Oncology • Casa Grande, AZ

Physician

Join to view full profile

Dr. Arce-Lara is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arce-Lara's full profile

Already have an account?

Office
1876 E Sabin Dr
Ste 10
Casa Grande, AZ 85122
Phone+1 520-836-9800

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2007
University of Louisville School of MedicineFellowship, Hematology and Medical Oncology, 2004 - 2005
Mercy Catholic Medical CenterResidency, Internal Medicine, 2001 - 2004
Universidad de Ciencias MedicasClass of 1999

Certifications & Licensure

AZ State Medical License 2018 - 2026
WI State Medical License 2012 - 2019
TX State Medical License 2008 - 2014
OH State Medical License 2005 - 2009
KY State Medical License 2004 - 2006
PA State Medical License 2001 - 2004
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Mar 01
Active, not recruiting
Phase 1, Phase 2
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Start of enrollment: 2017 Oct 17
Completed
Phase 2
Roles: Contact

Publications & Presentations

PubMed

23 citations
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.
Richard F. Ambinder, Juan Wu, Brent R. Logan, Christine M. Durand, Ryan K. Shields
Biology of Blood and Marrow Transplantation. 2019-11-01
12 citations
Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.
Binod Dhakal, Anita D'Souza, Mehdi Hamadani, Carlos Arce-Lara, Katrina Schroeder
Blood Cancer Journal. 2019-07-29
20 citations
A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative ...
Parameswaran Hari, Omar S. Aljitawi, Carlos Arce-Lara, Rajneesh Nath, Natalie S. Callander
Biology of Blood and Marrow Transplantation. 2015-12-01

Lectures

Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Breast Cancer Diagnosis? Ask These 5 QuestionsNovember 16th, 2024
American Oncology Network Launches New Cancer FoundationNovember 8th, 2023